ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,205.40
0.68%
S&P ASX All Technology
3,511.30
1.43%
Brent Oil
77.635
0.33%
US Dollar vs AUD
1.47079
0.01%
Bitcoin
63,480.54
1.06%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Assertio Holdings Inc (ASRT) Share Price

Assertio Holdings Inc

Assertio Holdings Inc (ASRT)

BNP Paribas Asset Management Luxembourg
1.14
0.05
(4.59%)
Closed 07 October 7:00AM
Delayed by 15 minutes
1.13
-0.01
(-0.88%)
After Hours: 8:56AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.13
Bid
1.09
Offer
1.22
Volume
427,049
1.09 Day's Range 1.14
0.7324 52 Week Range 2.60
Market Cap
107.729M
Previous Close
1.09
Open
1.11
Last Trade
400
@
1.13
(formt)
Last Trade Time
Financial Volume
US$ 476,140
VWAP
1.115
Average Volume (3m)
732,922
Shares Outstanding
95,335,629
Dividend Yield
-
PE Ratio
-0.33
Earnings Per Share (EPS)
-3.48
Revenue
152.07M
Net Profit
-331.94M

About Assertio Holdings Inc

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management... Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.assertiotx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Assertio Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ASRT. The last closing price for Assertio was US$1.09. Over the last year, Assertio shares have traded in a share price range of US$ 0.7324 to US$ 2.60.

Assertio currently has 95,335,629 shares in issue. The market capitalisation of Assertio is US$103.92 million. Assertio has a price to earnings ratio (PE ratio) of -0.33.

Ask ADVFN Intelligence (AI)

ASRT Latest News

More News

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

05 October 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

04 October 2024
Edgar (US Regulatory)

Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024

LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

04 September 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 August 2024
Edgar (US Regulatory)

Form 8-K - Current report

08 August 2024
Edgar (US Regulatory)

Assertio Reports Second Quarter 2024 Financial Results

Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term...

08 August 2024
GlobeNewswire Inc.

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

25 July 2024
GlobeNewswire Inc.

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

10 July 2024
GlobeNewswire Inc.

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

07 June 2024
GlobeNewswire Inc.

Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024

LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...

05 June 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.07-5.833333333331.21.2481.094996261.1425321CS
4-0.14-11.02362204721.271.381.094486971.22748268CS
12-0.62-35.42857142861.751.7981.047329221.32465375CS
260.208722.65277325520.92131.7980.73248113411.19630516CS
52-1.29-53.3057851242.422.60.732410448591.23494927CS
1560.230725.6532858890.89938.010.732413028343.21058331CS
260-0.11-8.870967741941.248.010.3323170671.66021418CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CHSNChanson International Holding
US$ 11.22
(269.08%)
14.76M
PEVPhoenix Motor Inc
US$ 1.0607
(205.24%)
228.42M
ENTOEntero Therapeutics Inc
US$ 0.60
(72.20%)
10.42M
BENFBeneficient
US$ 1.8914
(58.94%)
108.31M
FORDForward Industries Inc
US$ 5.3254
(52.15%)
18.45M
ADDColor Star Technology Company Ltd
US$ 0.2701
(-39.98%)
15.01M
DUOFangDD Network Group Ltd
US$ 2.53
(-32.89%)
28.52M
ICCTiCoreConnect Inc
US$ 0.4102
(-31.50%)
1.68M
ZENAZenaTech Inc
US$ 3.91
(-29.55%)
213.24k
SPAISafe Pro Group Inc
US$ 1.93
(-25.77%)
239.89k
NVDANVIDIA Corporation
US$ 124.92
(1.68%)
244.46M
PEVPhoenix Motor Inc
US$ 1.0607
(205.24%)
228.42M
SQQQProShares UltraPro Short QQQ
US$ 7.43
(-3.63%)
184.47M
NCNCnoco noco Inc
US$ 0.144
(8.60%)
147.38M
BENFBeneficient
US$ 1.8914
(58.94%)
108.31M

ASRT Discussion

View Posts
dcaf7 dcaf7 3 months ago
H.C. Wainwright starts Assertio at buy.
The investment bank said it believes Rolvedon could reach peak annual sales of around $140M in the early 2030s. It added that “long run positive traction” from products such as Rolvedon, Otrexup and Sympazan “ought to drive renewed interest from investors.”
The bank set its price target at $4.
👍️ 1
glenn1919 glenn1919 3 months ago
ASRT.......................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 months ago
ASRT................................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
ATLcitizen ATLcitizen 4 months ago
Heather Mason recently purchased 25K of ASRT shares.
👍️ 1
dcaf7 dcaf7 4 months ago
A meta-analysis of the effect of pegfilgrastim biosimilars and eflapegrastim on DSN was presented at ASCO. "Additionally, eflapegrastim, another long-acting granulocyte-colony stimulating factor agent, significantly reduced DSN compared to conventional pegfilgrastim (WMD, n = –0.13 days; 95% CI –0.24 to –0.03; P = .01). The researchers recommended “exploring the impact of the drug in clinical settings on costs and patient-reported outcomes could provide valuable insights into optimizing the management of chemotherapy-related neutropenia.”
https://www.centerforbiosimilars.com/view/asco-2024-posters-showcase-positive-data-on-denosumab-pegfilgrastim-biosimilars
👍️ 1
Propain Propain 4 months ago
bought some shares today. Gaurantee the stock will tumble now!
👍️0
dcaf7 dcaf7 5 months ago
Rolvedon/eflapegrastim is a new molecule. You cannot call it "novel formulation". Novel formulation of what? Neulasta? Nonsense.
👍️ 1
ATLcitizen ATLcitizen 5 months ago
dcaf7, please elaborate on what you mean?
👍️0
dcaf7 dcaf7 5 months ago
Listened to yesterday ASRT presentation. They call Rolvedon a "novel formulation" (slide 5). Looks like these guys don't know what Rolvedon really is.
👍️ 1
dcaf7 dcaf7 7 months ago
Rolvedon pediatric study is a postmarketing requirement from FDA. If it was up to Spectrum, they wouldn’t run it because of small commercial opportunity and approved Neulasta. I think completion of Phase 2 is what ASRT needs to accomplish. I doubt phase 3 will be required but they need to complete current study and to show the results to FDA that can happen 3-4 years away from now. As for Neulasta you can find that “no overall differences in safety were identified between adult and pediatric patients based on postmarketing surveillance”. As for same day dosing, I think, nobody knows what the next step looks like. Depends on data. Three years ago, JT said “If data is good, we would engage in a discussion with the FDA to path forward”. About a year ago, TR said the same, “whether that be going to chat with FDA about a regulatory path forward, whether it is publication, it is really contingent upon what we see in that data”.
👍️ 1
ATLcitizen ATLcitizen 7 months ago
A couple questions. A few days ago, a phase 2 study showed pediatric patients tolerated Rolvedon without requiring dose reduction. I could not copy link, but can find on Stocktwits ASRT from poster Avedesian. What is the significance? Does this mean Assertio may market to pediatric patients now, or phase 3 required? Also, this poster says that Neulasta and biosimilars required dose reduction for pediatric patients. Does this mean R is safer? How does this differentiate R from Neulasta and biosimilars? Next question: Hanmi recently said in interview with a Korean biopharma news that they expect R to be successful in their same day dosing trial to get a 'competitive edge'. IMO this appears to be a sign that they will continue with another study if the current study is successful. Another poster on X, claiming to be a doctor (this was copied on Stocktwits) said that they expect it to be short study due to requiring only one cycle of treatment. Any ideas of how long to complete another study, including enrollment? Should this be a quicker study? TIA!
👍️0
glenn1919 glenn1919 7 months ago
ASRT.........................https://stockcharts.com/h-sc/ui?s=ASRT&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 months ago
ASRT 10Q due March 11
👍️0
dcaf7 dcaf7 7 months ago
I don’t have an answer about what does it mean. I can explain why they will finish it earlier. Because they reduced the number of patients from 90 to 50. Good sign is that trial is still enrolling. It means they think that a positive outcome is still possible. What is next if the data is good? In my opinion, for approval they need to conduct a larger trial. Not sure if they want it.
👍️ 1
ATLcitizen ATLcitizen 7 months ago
The same day dosing trial for R has moved forward its study completion date from june 2025 to july 2024. Thoughts? Is this a good sign and if successful, what is next?
👍️0
dcaf7 dcaf7 8 months ago
Hanmi Pharma said it has signed a strategic agreement with its U.S. partner company, Assertio Holdings, which previously acquired Spectrum Pharmaceuticals, to re-acquire the rights to Rolontis, a long-acting neutropenia treatment and Korea's 33rd novel drug, for the Asian and African markets.
Published 2024.02.02

?? : KBR(https://www.koreabiomed.com)
👍️ 1
Monksdream Monksdream 8 months ago
ASRT new 52 week low
🌈 1 🍆 1 👎️ 1 🩳 1
dcaf7 dcaf7 9 months ago
What is interesting, Coherus said their injector is more patient friendly than what is used in Onpro. So, it looks like a competition of injectors now. Is it possible to win Neulasta market by introducing a better injector? Unexpected twist.
👍️ 1
ATLcitizen ATLcitizen 9 months ago
Good question, dcaf7!
👍️0
dcaf7 dcaf7 9 months ago
Shares of Coherus BioSciences (NASDAQ:CHRS) surged 36.4% after the FDA had approved an on-body injector version of the biosimilar – Udenyca for post-chemotherapy treatment Neulasta.
https://seekingalpha.com/news/4050413-biggest-stock-movers-today-coherus-biosciences-bit-digital
It will make more difficult for Rolvedon to compete. Why Spectrum or Assertio didn't start on-body injector program in addition to same day dosing?
👍️0
dcaf7 dcaf7 9 months ago
Hi ATLcitizen! Good to see you here. I think physicians view Ryzneuta the same way as Rolvedon. No clear differentiation from Neulasta. Assertio should work on same day dosing. As for Poziotinib, I don't know. I don't see any new trials with Pozi but I see several drug candidates in development that are less toxic. I found interesting document describing what exactly Spectrum did to be acquired. It looks like Hanmi was considering to buy Spectrum.
https://www.sec.gov/Archives/edgar/data/1808665/000110465923071264/tm2315184-6_s4a.htm
This acquisition story is described on pp71-82 step by step. Board was interested to sell the company when TR became a CEO. "Following the appointment of Thomas J. Riga as Spectrum’s President and Chief Executive Officer effective January 1, 2022, the Spectrum board of directors engaged in discussions regarding potential strategic alternatives at each of its regularly scheduled meetings and authorized Mr. Riga and the Spectrum management team to explore potential strategic alternatives".
👍️ 1
ATLcitizen ATLcitizen 9 months ago
What a shocker. I thought Pozi was dead. What do you think Hanmi is trying to do- get approval for 3rd line treatment? What about the whole dosing and side effects problem that FDA issued a CRL for--is Hanmi addressing that as far as you know? Do you know if MDA is still interested in investigating Pozi or have moved on? TIA.
👍️0
ATLcitizen ATLcitizen 9 months ago
Hi dcaf7! Found you again! What do you think of Ryzneuta?
👍️0
dcaf7 dcaf7 10 months ago
Ryzneuta was approved 3 weeks ago. Second "novel" long-acting G-CSF. Acrotech is going to market it in the US. It is same company that markets five Spectrum drugs.
https://acrotechbiopharma.com/wp-content/uploads/2023/11/Evive-and-Acrotech-Announce-FDA-Approval-of-Ryzneuta.pdf
👍️ 1
dcaf7 dcaf7 10 months ago
On Hanmi. Brokerages raise stock price targets for Korean traditional pharma citing licensing deals, export gains.
Daishin Securities set the target prices for Hanmi Pharm and Yuhan Corp. from the current 315,500 won and 63,300 won to 420,000 won and 92,000 won, respectively. Hanmi has strengths in the continued steady profit growth through the sales of key products like Rosuzet, Amozaltan family, and Rolvedon.
👍️0
dcaf7 dcaf7 11 months ago
Hanmi is ready to conduct a Phase 4 study "Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (NEUTHREE)". Title is misleading since they are using Eflapegrastim (Rolvedon), not Pegfilgrastim (Neulasta). You can see it in official title, "Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy". Here is a rationale for this study, "It is known that patients who experience neutropenia after the first round of chemotherapy are more likely to experience it again in subsequent rounds. The investigators aimed to see whether changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy for patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round can reduce the incidence of neutropenia".
https://classic.clinicaltrials.gov/ct2/show/NCT05949333?term=eflapegrastim&draw=2&rank=2
👍️ 1
Johnny R Johnny R 11 months ago
very disappointing earnings release . . . . and the insiders all sold their stock to cover taxes on their options . . . . sure, whatever you say
👍️0
Johnny R Johnny R 11 months ago
wow that has been kept quiet. I presume it will be discussed in the quarterly earnings call
👍️0
dcaf7 dcaf7 11 months ago
Hanmi posted 3dQ results. In their presentation you can find, "pan HER - preparing for global phase 3 trial" with Assertio as a partner.
http://www.hanmi.co.kr/upfile/ces/information/INFORMATION_PRESENTATIONS/90166507/127540fe-3519-4cb1-95bb-0ce29cb172ee.pdf
👍️0
dcaf7 dcaf7 1 year ago
From VA Formulary Advisor.
Projected Place in Therapy/Conclusions
• In 2 phase III clinical trials in patients with early breast cancer receiving myelosuppressive chemotherapy for 4
cycles in the adjuvant setting, eflapegrastim was non-inferior to pegfilgrastim in reducing the duration of severe
neutropenia during cycle 1 (primary endpoint) and during cycles 2-4 (secondary endpoint). Pooled rates of febrile
neutropenia for this chemotherapy combination without G-CSF prophylaxis are 29.1%.
• Safety during the clinical trial (adverse reactions in ≥20%) was similar between eflapegrastim and pegfilgrastim
despite the fact that eflapegrastim provides a lower dose of G-CSF compared to pegfilgrastim. The package
labeling for both products contains the same contraindication and Warnings and Precautions.
• There is no clear place in therapy for eflapegrastim instead of pegfilgrastim.
https://www.va.gov/formularyadvisor/DOC/466
👍️0
dcaf7 dcaf7 1 year ago
Ha ha. Good job. Posted by Defense World Staff on Aug 25th, 2023. Equities research analysts at StockNews.com began coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Free Report) in a note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
👍️0
dcaf7 dcaf7 1 year ago
Rolvedon vs biosimilars cost.
The final 2 articles highlighted in this issue of the Medical Letter address the question of cost. The first notes the recent approval of the new bone marrow stimulatory agent eflapegrastim-xnst (Rolvedon) for the prevention of chemotherapy-induced febrile neutropenia. The agent was FDA approved based on the results of 2 randomized trials in which it demonstrated noninferiority in one trial and possible superiority in the other trial vs pegfilgrastim (Neulasta).

Although there should always be interest in discovering novel, increasingly effective, less toxic approaches to supportive care measures in cancer management, the question here is the value of such agents vs less expensive biosimilar agents employed for this purpose. One dose of eflapegrastim is said to cost $4500 compared with pegfilgrastim biosimilar costing approximately $2500. This sum is not insignificant considering the common use of bone marrow stimulatory agents by oncology practices and health care systems, as well as the financial impact on third-party payers or as increasingly mandated insurance co-pay for individual patients.
https://www.onclive.com/view/unresolved-issues-in-antineoplastic-drug-therapy-is-it-finally-time-to-address-
👍️ 2
rado rado 1 year ago
A few quotes from the call from Dan Peisert

"We believe we can certainly accelerate the path to profitability, and possibly accelerate the trajectory to a broader reach than what the in-person team has been able to do to date to drive awareness to physicians as well as to purchasing managers."

"... should enhance our access to the capital markets at a lower cost of capital than either company had on a standalone basis and accelerate our future M&A strategies so we can leverage both our platforms with complementary assets..."

"...but the synergies will come largely from the contracting and the access teams that will be a tremendous benefit to rest of the Assertio portfolio"

Dan Peisert also noted that this accelerate their plans and be highly accretive in 2024 and that this is a blockbuster product. There was some mention of 600+ clinics that Spectrum had access to whereas ASRT had access to 2000+ clinics. So the Spectrum product will get advertised more broadly than before, ASRT will probably get access to new clinics and relationships with their non-contact platform.
👍️0
rado rado 1 year ago
The ASRT purchase conference call
https://events.q4inc.com/attendee/994427686/guest?t=1682444171300
👍️0
1hot toddy 1hot toddy 1 year ago
WOOOOOOOOOOW 2-10K BUYS, ONE 5K BUYS. SMART MONEY BUYING NOT SELLING $$$$$$$$$$
👍️0
saigai saigai 2 years ago
well now..seems like this is the ground floor..saw it a while back and forgot about it so i could have gotten in earlier but im happy.. this is a real equity building event they will leverage some very important assets to shoot the moon.. the best part is the cash position and cfp of many milions a year.. a cash cow..,,enjoy while we can
👍️0
saigai saigai 2 years ago
i dont want to see the 5 dollar space anymore i want 50 but not today because i am doubling up tomorrow.. this is the one that gets me back in the game just need to be patient
👍️0
1hot toddy 1hot toddy 2 years ago
221000 SHARE BUY ON THE CLOSE $$$$$$$$$$$$$$$$ OVER MIL $ BUY
👍️0
saigai saigai 2 years ago
shorts having a field day
👍️0
Alan Brown Alan Brown 2 years ago
Going up ~
👍️0
crawford2012 crawford2012 2 years ago
$Assertio Holdings Inc This is a very smart move by the company, here is why and what it does. In short, buy the friking dip.
These transactions?? reduce our overall debt by $30M, or 42.9%, while consuming only $10.5M in cash (and issue ~$7M shares). In addition, the transactions will ??save the company $2M in annual interest payments, reduce the potential dilution from the exchanged convertible notes by 4.6%, and will be accretive to our diluted EPS by $0.02 in 2023," CEO Dan Peisert commented.

??????????????????????????????
👍️0
saigai saigai 2 years ago
wish i had some powder to put here
👍️0
yankee2 yankee2 3 years ago
ASRT $3.00 Looking good so far

https://www.barchart.com/stocks/quotes/ASRT/technical-chart?plot=CANDLE&volume=total&data=DO&density=X&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);SRSI(14,14);WILLR(14,40);ADX(14);ACCUM;MACD(12,26,9);RSI(14,100);SMA(50)&sym=ASRT&grid=1&height=500&studyheight=100


glta
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ASRT picking up speed now!!!
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ASRT ...rock star biotech!!!
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ASRT the trend is your friend
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ASRT wowza...trading to perfection!
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ASTR ready to go
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
ASRT...one of the best and safest bio plays!!
👍️0
TrendTrade2016 TrendTrade2016 3 years ago
BIO season kicking in...ASRT shaping up!!
👍️0

Your Recent History

NASDAQ
ASRT
Assertio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved